During the weekend, Sprint Bioscience announced that the US firm Day One has decided to discontinue ...
Redeye returns with a more in-depth take on the Q1 report.
Digging into the feasibility study and mineral resource update Feasibility study arrives an NPV of S...
Redeye provides a research update following the Q1 report recently published by Initiator Pharma.
Redeye provides a research update following Catella’s Q1 2025 report.
Redeye returns with positive estimate adjustments following I-Tech's Q1 2025 report that delivered s...
Q1e: top line and adj. EBITDA +14% and 9% y-o-y '25e-'27e sales down 3%, limited adj.
Redeye provides a brief comment on the news that 85% of the TO 12 warrant program has been secured a...
Nettoomsättningen uppgick till 204,6 MSEK (199,3), vilket motsvarade en ökning med 2,7% y-o-y.
EQL Pharma redovisade ökad nettoomsättning och EBIT i det fjärde kvartalet.
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har publicerat Koncernens delår...
Ahead of Relais Q1, we maintain our estimates intact.
Redeye is optimistic about Alligator’s completion of GMP production of mitazalimab, a precondition f...
Q1 adj. EBIT -1% vs ABG, but -10% vs. consensus We cut adj.
Redeye provides an initial comment on Catella’s Q1 2025 report.
Balanced regional growth with broad-based support from the Medical Device segment.
Redeye updates on W5 Solutions following a softer than expected Q1-report.
CapMan’s fee income of EUR 13.0m grew 8% y/y and was fairly in line with our estimate of EUR 13.
Redeye updates its estimates after reviewing Tessin's Q1 report, which came in below expectations.
Redeye provides an update following Truecaller’s Q1 2025 report, which came in softer than expected.
